<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133536</url>
  </required_header>
  <id_info>
    <org_study_id>04-077</org_study_id>
    <nct_id>NCT00133536</nct_id>
  </id_info>
  <brief_title>A/H5N1 Vaccine in Healthy Children Aged 2-9 Years</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years Through 9 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purposes of this study are: to make sure that there are no serious side effects of an
      experimental inactivated influenza A/H5N1 vaccine in children; and to see how the body's
      immune system reacts to the vaccine. To look at the side effects, researchers will follow
      children closely after vaccination. To look at immune system responses, researchers will test
      the children's blood before and a number of times after vaccination. Participants will
      include up to 130 healthy children ages 2-9 years. Participants will be assigned to receive
      2, up to 3 doses of vaccine, or placebo (inactive substance). Subjects will receive at least
      2 doses of vaccine approximately 28 days apart. If data shows an enhanced immune response
      from a third vaccination, children will be offered a third dose of the vaccine. Participants
      will be involved in study related procedures for up to 13 months, including up to 6 study
      visits, plus a number of telephone calls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of this study are to assess the safety, reactogenicity, and immunogenicity of
      45-microgram dosage level of monovalent subvirion influenza A/H5N1 virus vaccine administered
      by intramuscular (IM) route to healthy children. The primary goal of this study is to
      determine if this dosage level of H5N1 will result in an acceptable proportion of children
      achieving a potentially protective post vaccination antibody titer (provisionally assigned as
      a serum neutralizing titer of 1:40, based on studies conducted in Hong Kong during the 1997
      H5N1 outbreak). Approximately 130 healthy children, aged 2 through 9 years, will be enrolled
      in this multicenter, randomized, double-blinded, placebo-controlled, clinical trial to
      receive at least 2 and up to 3 doses of an inactivated influenza A/H5N1 vaccine at a
      45-microgram dose. One hundred subjects will be enrolled and randomly assigned into the
      influenza A/H5N1 vaccine dose group and 20 subjects into the placebo group (in 5:1 ratio).
      Subjects will be stratified into 2 age groups (2 to 5 years old and 6 to 9 years old).
      Vaccine or placebo will be administered into the deltoid. Subjects randomized to receive
      vaccine will receive 2 doses of the vaccine approximately 28 days apart. At approximately
      month 5, subjects' parent(s) or guardian(s) will be called to remind them of the 6-month
      follow-up visit. At the 6-month visit, subjects will be assessed for serious adverse events
      (SAEs) and the randomization assignment, ie, to vaccine or placebo, will be unmasked to the
      subject and parent(s) or guardian(s). Should data evaluating a third dose of the influenza
      A/H5N1 vaccine in adults show enhanced immunogenicity, parents or guardians of subjects who
      received vaccine will be offered a third dose, with an additional blood draw immediately
      prior to the third dose and 28 days and 6 months thereafter. The 6-month post-Dose 3 blood
      draw is optional. For subjects assigned to placebo, the parents or guardians will be offered
      the opportunity to enroll the subject into a separate open-label protocol if the 2 dose
      regimen administered to the vaccine recipients is found to be safe and immunogenic. The
      primary endpoints of the study include: adverse event (AE) and SAE information (solicited
      in-clinic and via memory aids, concomitant medications, and periodic targeted physical
      assessments, as indicated); proportion of subjects achieving a serum neutralizing antibody
      titer of 1:40 against the influenza A/H5N1 virus 28 days after receipt of second dose of
      vaccine (approximately Day 56); and geometric mean titer (GMT) and the frequency of 4-fold or
      greater increases in hemagglutination inhibition and neutralizing antibody titers 28 days
      after receipt of second dose of vaccine (approximately Day 56). The secondary endpoints of
      the study include: proportion of subjects achieving a serum neutralizing antibody titer of
      1:40 against the influenza A/H5N1 virus 1 and 6 months after receipt of first and third doses
      (if third dose will be administered [see study design]) of vaccine; GMT and the frequency of
      4-fold or greater increases in serum hemagglutination inhibition antibody titer 1 and 6
      months after receipt of first and third (if third dose will be administered [see study
      design]) doses of vaccine; and development of serum antibody responses against antigenically
      drifted variants of influenza H5N1 virus. This study is linked to protocol 06-0072.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event (AE) and serious adverse event (SAE) information (solicited in clinic and via memory aids, concomitant medications, and periodic targeted physical assessments.)</measure>
    <time_frame>Solicited AEs-reactogenicity following each vaccination. Unsolicited AEs-SAEs occurring during the length of the study, and nonserious events occurring 28 days after receipt of the 2nd (from enrollment) or 3rd dose of vaccine.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving a serum neutralizing antibody titer of 1:40 against the influenza A/H5N1 virus.</measure>
    <time_frame>28 days after receipt of the 2nd dose of vaccine (Day 56).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer and the frequency of 4-fold or greater increases in hemagglutination inhibition and neutralizing antibody titers.</measure>
    <time_frame>28 days after receipt of the 2nd dose of vaccine (Day 56).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a serum neutralizing antibody titer of 1:40 against the influenza A/H5N1 virus.</measure>
    <time_frame>1 and 6 months after receipt of first and third doses (if third dose will be administered [see study design]) of vaccine.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer and the frequency of 4-fold or greater increases in serum hemagglutination inhibition antibody titer.</measure>
    <time_frame>1 and 6 months after receipt of first and third (if third dose will be administered [see study design]) doses of vaccine.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of serum antibody responses against antigenically drifted variants of influenza H5N1 virus.</measure>
    <time_frame>Blood samples for serum assays will be collected at day 0, approximately 1 month after each immunization, and approximately 6 months after the first immunization and third immunization (if provided).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 subjects 45 mcg of influenza A/H5N1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 subjects saline placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza A/H5N1 Vaccine</intervention_name>
    <description>Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline administered intramuscularly.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must be male or female, aged 2 through 9 years at enrollment.

          -  The subject must be in good health (and not on any chronic medications), as determined
             by medical history and a history-directed targeted physical examination.

          -  Parents or guardians must be able to understand and comply with planned study
             procedures and be available for all study visits.

          -  Parents or guardians must provide written consent prior to initiation of any study
             procedures, and subject may provide written assent as appropriate.

        Exclusion Criteria:

          -  The subject must not have a known allergy to eggs or other components of the vaccine
             or sensitivity or allergy to latex.

          -  The subject must not have a history of asthma or recurrent wheezing.

          -  The subject must not be undergoing immunosuppression as a result of an underlying
             illness or treatment.

          -  The subject must not have an active neoplastic disease or a history of any hematologic
             malignancy.

          -  The subject must not be using oral or parenteral steroids, inhaled steroids, or other
             immunosuppressive or cytotoxic drugs. Note: Subjects on nasal or topical steroids will
             be allowed to enroll in this study.

          -  The subject must not have a history of receiving immunoglobulin or other blood product
             within the 3 months prior to enrollment in this study.

          -  The subject must not have received any other licensed vaccines within 2 weeks (for
             inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this
             study.

          -  The subject must not have an acute or chronic medical condition that, in the opinion
             of the investigator, would render vaccination unsafe or would interfere with the
             evaluation of responses (these conditions include, but are not limited to, known
             chronic liver disease, significant renal disease, unstable or progressive neurological
             disorders, diabetes mellitus, and transplant recipients).

          -  The subject must not have a history of severe reactions following immunization with
             contemporary influenza virus vaccines.

          -  The subject must not have an acute illness, including an axillary temperature greater
             than 100 degrees F, within 3 days prior to vaccination.

          -  The subject must not have received an experimental vaccine or medication within one
             month prior to enrollment in this study, or expect to receive an experimental vaccine,
             medication, or blood product during the 13-month study period.

          -  The subject must not have any condition that would, in the opinion of the
             investigator, place them at an unacceptable risk of injury or render the subject
             unable to meet the requirements of the protocol.

          -  History of Guillain-Barr√© syndrome.

          -  The subject must not be participating concurrently in another clinical trial (either
             in active phase or in follow-up phase).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Center For Vaccine Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Johnson</name_title>
    <organization>HHS/NIAID/DMID</organization>
  </responsible_party>
  <keyword>H5N1, Influenza, children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

